New painkiller, with fewer side-effects, up for FDA approval

Published on April 23, 2014 at 12:43 AM · No Comments

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro.

NPR: Powerful Narcotic Painkiller Up For FDA Approval
The Food and Drug Administration is trying to decide whether to approve a powerful new prescription painkiller that's designed to relieve severe pain quickly, and with fewer side effects than other opioids. While some pain experts say the medicine could provide a valuable alternative for some patients in intense pain, the drug (called Moxduo) is also prompting concern that it could exacerbate the epidemic of abuse of prescription painkillers and overdoses. An FDA advisory committee is holding a daylong hearing Tuesday to decide whether to recommend that the agency approve the drug (Stein, 4/22).

CQ Healthbeat: FDA Official Urges Reassessment Of Painkiller Use
While defending the approval of the controversial painkiller Zohydro, the top U.S. drug regulator is calling for a reversal of the trends that have triggered excess use of narcotics in the United States and unleashed an epidemic of prescription drug abuse (Young, 4/22).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine